On June 16, 2026, Oncolytics Biotech Inc. announced the issuance of a new patent concerning the manufacturing of pelareorep and provided updates regarding the drug's intellectual property portfolio. The company operates in the biotechnology industry and develops immunotherapies for the treatment of cancer.
